Diagonal Bio AB (publ) reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was SEK 0.583 million compared to SEK 2.84 million a year ago. Revenue was SEK 0.597 million compared to SEK 2.86 million a year ago. Net loss was SEK 3.38 million compared to SEK 0.727 million a year ago. Basic loss per share from continuing operations was SEK 0.37 compared to SEK 0.14 a year ago.